Rapid onset of response and patient-reported outcomes after onabotulinumtoxin A treatment of moderate-to-severe glabellar lines

Journal of Drugs in Dermatology

Volumn 10, Issue 1, 2011, Pages 39-44

  Beer, Kenneth R ^a   Boyd, Charles ^b   Patel, Rina K ^c   Bowen, Beta ^c   James, Steven P ^c   Brin, Mitchell F ^c,d  

^a Palm Beach Esthetic Center   (United States)

^b Boyd Cosmetic Surgical Institute   (United States)

^c ALLERGAN INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FACIAL WRINKLE SCALE; FEMALE; GLABELLAR LINE; HEADACHE; HUMAN; OPEN STUDY; SKIN DISEASE; TOOTH ABSCESS; TREATMENT RESPONSE;

ADULT; BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; PATIENT SATISFACTION; QUESTIONNAIRES; SKIN AGING; TIME FACTORS; TREATMENT OUTCOME;

EID: 80053027080     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Carruthers A, Carruthers J, Lowe NJ, et al., for the BOTOX® Glabellar Lines I & II Study Groups. One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. J Clin Res. 2004;7:1-20. (Pubitemid 38843595)
2. Carruthers A, Carruthers J, Said S. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg. 2005;31:414-422. (Pubitemid 40489301)
3. Carruthers A, Carruthers J. Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg. 2005;31:1297-1303. (Pubitemid 41587037)
4. Harii K, Kawashima M. A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plast Surg. 2008;32:724-730.
5. Kawashima M, Harii K. An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. Int J Dermatol. 2009;48:768-776.
6. Brin MF, Boodhoo TI, Pogoda JM, et al. Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: A meta-analysis of individual patient data from global clinical registration studies in 1678 participants. J Am Acad Dermatol. 2009;61:961-970.
7. Carruthers A, Carruthers J. Long-term safety review of subjects treated with botulinum toxin type A for cosmetic use. Poster presented at: Proceedings of the 13th Congress of the European Academy of Dermatology & Venereology; November 17-21, 2004; Florence, Italy.
8. Fagien S, Carruthers JDA. A comprehensive review of patient-reported satisfaction with botulinum toxin type A for aesthetic procedures. Plast Reconstr Surg. 2008;122:1915-1925.
9. Flynn TC. Botulinum toxin: Examining duration of effect in facial aesthetic. Am J Clin Dermatol. 2010;11:183-199.
10. Fagien S, Cox SE, Finn JC, et al. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: A double-blind, randomized, placebo-controlled study. Dermatol Surg. 2007;33:S2-S9. (Pubitemid 46051393)
11. Carruthers J, Carruthers A. Botulinum toxin type A treatment of multiple upper facial sites: patient-reported outcomes. Dermatol Surg. 2007;33:S10-S17. (Pubitemid 46051394)
12. Beer KR. Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatol Surg. 2006;32:184-192.
13. Blitzer A, Binder WJ, Aviv JE, et al. The management of hyperfunctional facial lines with botulinum toxin: A collaborative study of 210 injection sites in 162 patients. Arch Otolaryngol Head Neck Surg. 1997;123:389-392. (Pubitemid 27180937)
14. Sloop RR, Escutin RO, Matus JA, et al. Dose-response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type A. Neurology. 1996;46:1382-1386. (Pubitemid 26164651)
15. Hamjian JA, Walker FO. Serial neurophysiological studies of intramuscular botulinum-A toxin in humans. Muscle Nerve. 1994;17:1385-1392. (Pubitemid 24362810)
16. Carruthers A, Carruthers J. A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. J Drugs Dermatol. 2009;8:924-929.
17. Botox Cosmetic [package insert]. Irvine, CA: Allergan, Inc.; 2010.
18. Blitzer A, Brin MF, Fahn S, Lovelace RE. Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia). Laryngoscope. 1988;98:193-197. (Pubitemid 18052677)
19. Blitzer A, Brin MF. Laryngeal dystonia: A series with botulinum toxin therapy. Ann Otol Rhinol Laryngol. 1991;100:85-89.
20. Grillone GA, Blitzer A, Brin MF, et al. Treatment of adductor laryngeal breathing dystonia with botulinum toxin type A. Laryngoscope. 1994;104:30-32. (Pubitemid 24028033)
21. Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord. 1987;2:237-254.
22. Brandt F, Swanson N, Baumann L, Huber B. Randomized, placebo-controlled study of a new botulinum toxin type A for treatment of glabellar lines: Efficacy and safety. Dermatol Surg. 2009;35:1893-1901.
23. Rubin MG, Dover JS, Glogau RG, et al. The efficacy and safety of a new U.S. botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. J Drugs Dermatol. 2009;8:439-444.
24. Moy R, Maas C, Monheit G, Huber B; for the Reloxin Investigation Group. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg. 2009;11:77-83.
25. Kane MA, Rohrich RJ, Narins RS, et al The Reloxin Investigational Group. Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: Results from a phase III, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg. 2009;124:1619-1629.
26. Chapman MA, Barron R, Tanis DC, et al. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin Ther. 2007;29:1325-1337. (Pubitemid 47348118)